Bulk Pharmaceutical API Sources for TECHNETIUM TC-99M SODIUM PERTECHNETATE

Bulk Pharmaceutical API Sources for TECHNETIUM TC-99M SODIUM PERTECHNETATE

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		23689036
BenchChem		B1261141
THE BioTek		bt-1593333

Bulk Active Pharmaceutical Ingredient (API) Sources for: Technetium Tc-99m Sodium Pertechnetate

Last updated: August 6, 2025

Introduction

Technetium-99m (Tc-99m) sodium pertechnetate is a cornerstone radiopharmaceutical used extensively in diagnostic nuclear medicine. Its pivotal role in imaging procedures, including brain, thyroid, and cardiovascular scans, underscores the importance of a reliable and compliant supply chain of high-quality API. As a radiopharmaceutical, the API sourcing landscape is complex, governed by manufacturing constraints, radiation safety regulations, and the single-source nature of the isotope production process.

Overview of Tc-99m API Production

Tc-99m is produced from molybdenum-99 (Mo-99) decay via generator systems, primarily through technetium generators containing Mo-99 adsorbed onto an alumina column. The transition from Mo-99 to Tc-99m allows for sterile elution, converting the long-lived Mo-99 into the short-lived Tc-99m isotope. The key challenge is the consistent, high-purity production of Mo-99, which subsequently influences the quality and availability of Tc-99m pertechnetate.

The API for Tc-99m, i.e., the pertechnetate solution, is thus derived from Mo-99 generators. Manufacturers of these generators employ specific nuclear reactors, such as research reactors or isotope-specific dedicated reactors, to produce Mo-99 through fission of uranium targets or neutron activation of Mo-98.

Leading Global Suppliers of Mo-99 and Tc-99m Generators

Multiple organizations dominate global Mo-99 and Tc-99m generator production, forming the backbone of Tc-99m API supply. Notably:

• Nordion (Canada): Operates the NorthStar® Medical Technologies Mo-99 production via low-enriched uranium (LEU) fission, providing high-quality generators with rigorous safety and quality standards.

• Eckert & Ziegler (Germany): A major provider of Mo-99 and associated Tc-99m generators, with extensive global distribution networks.

• NTP Radioisotopes (South Africa): Offers Mo-99 produced from HEU and LEU targets, supplying various generator types.

• Curium (France/Sweden): Supplies Mo-99 from the Melox reactor, and produces Tc-99m generators for hospital and central radiopharmacies.

• Laboratories in the United States: Companies such as Covidien (now part of Medtronic), Lantheus Medical Imaging, and others produce Tc-99m generators from imported Mo-99 or domestically produced Mo-99.

Emerging and Alternative Source Developments

Given the aging infrastructure of traditional reactor-based Mo-99 production and the geopolitical risks associated with supply concentration, alternative methods and new suppliers are increasingly important:

• Cyclotron-based production: Several research initiatives and commercial endeavors, such as those by IBA and GE Healthcare, focus on producing Tc-99m directly via cyclotrons, bypassing reactor dependence. While promising, this approach faces regulatory and technological hurdles to become a reliable API source.

• LEU-based Mo-99: Countries pivoting to low-enriched uranium targets improve nuclear proliferation safety and potentially diversify the supply chain. The upcoming facilities, such as the Australian National Medical Cyclotron, aim to provide alternatives.

• Generator manufacturers: They play a vital role as the API's custodians, providing the final sterile eluate used in clinical settings. The primary companies involved globally include Nordion (Canada), Eckert & Ziegler (Germany), and Curium (France), with other regional players contributing.

Regulatory and Quality Considerations

Security of the Tc-99m API is intricately linked to the regulatory landscape, with agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and similar bodies worldwide setting stringent standards for purity, sterility, and radiation safety. Good Manufacturing Practice (GMP) compliance is mandatory at all stages, from Mo-99 production to final elution.

The raw material, Mo-99, must have high radionuclidic purity, minimal contaminants, and undergo rigorous quality control testing. The generator system, which functions as the API source, must also be validated for elution efficiency, stability, and sterility, affecting the consistency of Tc-99m supplies.

Supply Chain Challenges

• Reactor outages: The reliance on few aging reactors (e.g., NRU at Chalk River, Canada) led to shortages, such as the 2009 and 2018 disruptions.

• Production capacity: Limited global reactor capacity constrains the volume of Mo-99 available.

• Logistics: The short half-life of Tc-99m (6 hours) necessitates rapid distribution, making geographic proximity to production sites critical.

• Regulatory hurdles: Variations in country-specific approvals for generator types and API quality impact availability.

• Environmental and political factors: Nuclear policy changes and geopolitical tensions may influence international supply agreements.

Key Suppliers and Notable Projects

Supplier	Location	Production Focus	Noteworthy Projects	Notes
Nordion	Canada	Mo-99 generators	NorthStar®	Supplies >50% of U.S. demand; transitioning to LEU-based production
Eckert & Ziegler	Germany	Mo-99 and Tc-99m generators	IsoFor™	Global vendor with extensive distribution network
Curium	France/Sweden	Mo-99 production and generators	MUlTIGEN®	Focuses on stability and high-quality supply
NTP Radioisotopes	South Africa	Mo-99 from LEU/HEU	NTP	Significant supplier for Africa and Europe
Isotope Technologies Munich (ITM)	Germany	Cyclotron-produced Tc-99m	Emerging	Focuses on cyclotron-produced Tc-99m as API

Future Outlook

The global Tc-99m API supply landscape is headed toward diversification, driven by:

• New reactor facilities: Australia, Belgium, and India advancing reactor-based Mo-99 production to reduce reliance on aging reactors.

• Cyclotron initiatives: Companies progressing towards regulatory approval of cyclotron-produced Tc-99m as API, promising a decentralized and resilient supply.

• Reprocessing and recycling: Advances in Mo-99 reprocessing aim to maximize yields and reduce waste.

• Enhanced logistics: Innovations in rapid shipping and regional production centers improve supply robustness.

Conclusion

Securing a reliable supply of high-purity Tc-99m sodium pertechnetate API hinges on multiple factors—including upstream Mo-99 production, generator manufacturing, regulatory compliance, and geopolitical stability. The dominant global suppliers—Nordion, Eckert & Ziegler, and Curium—remain central, but diversification through cyclotron production and new reactor projects will be pivotal. Stakeholders must closely monitor technological developments and geopolitical shifts to ensure continuity in this critical diagnostic radiopharmaceutical.

---

Key Takeaways

• The core API source for Tc-99m sodium pertechnetate is derived from Mo-99 generators produced mainly in a limited number of nuclear reactors worldwide.

• Major global suppliers include Nordion, Eckert & Ziegler, and Curium, each offering high-quality, regulated Mo-99 and Tc-99m generator products.

• Supply chain disruptions have historically stemmed from reactor outages, highlighting the need for alternative production methodssuch as cyclotrons and LEU-based reactors.

• Regulatory compliance, radionuclidic purity, and quality assurance are critical factors influencing API sourcing and supply stability.

• The industry is shifting towards diversification and innovation, including cyclotron-based Tc-99m production, to create a resilient, sustainable API supply landscape.

---

FAQs

Q1: What are the primary challenges in sourcing Tc-99m sodium pertechnetate API?
A: Challenges include reliance on aging nuclear reactors for Mo-99 production, supply disruptions from reactor outages, complex regulatory requirements, and logistical constraints due to Tc-99m's short half-life.

Q2: Are there alternatives to reactor-produced Mo-99 for Tc-99m API?
A: Yes, emerging technologies include cyclotron-based production of Tc-99m directly and LEU-based Mo-99 generators, which aim to diversify and stabilize the supply chain.

Q3: How does regulatory compliance influence the quality of Tc-99m API?
A: Regulatory standards require high radionuclidic purity, sterility, and specific activity for Tc-99m API, ensuring safety and efficacy. Non-compliance risks supply rejection and patient safety.

Q4: Which regions are leading in Tc-99m API production?
A: North America (Nordion, Lantheus), Europe (Eckert & Ziegler, Curium), and South Africa (NTP) are major players, with ongoing initiatives worldwide to expand and diversify sources.

Q5: What is the future of Tc-99m API supply?
A: The future involves increased use of cyclotron-produced Tc-99m, new reactor projects to replace aging facilities, and improved logistics, all aimed at ensuring a resilient and sustainable supply chain for nuclear medicine diagnostics.